Placeholder Banner

New Report Shares Best Practices for the Development of Disease-Specific Patient Preference Studies

June 8, 2016

San Francisco, CA (June 8, 2016) – Today, the Biotechnology Innovation Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) released a new report, “Key Considerations for Developing and Integrating Patient Perspectives in Drug Development: Examination of the Duchenne Case Study.”

The report draws upon the pioneering work of PPMD and the Duchenne muscular dystrophy community in launching a milestone patient preference study and a community-led draft Guidance for integrating patient and caregiver perspectives into drug development and regulatory decision making. It outlines key considerations and decision-making processes for obtaining data on patient perspectives, and more specifically on patients’ stated preferences, that can be integrated into the drug development process.

“Patients today play an increasingly important and proactive role in developing drugs that will best meet their needs,” said BIO President and CEO Jim Greenwood. “This report provides much-needed guidance for companies seeking to incorporate the patient perspective at every stage of developing and delivering innovative new treatments.”

“Every patient has a story and every story has incredible value.  Translating these perspectives into rigorous data is a way to give voice to perspectives and integrate what matters most to patients into the drug development process,” said Pat Furlong, Founding President and CEO, Parent Project Muscular Dystrophy.

The report was guided by an Expert Review Committee (ERC) of thought leaders representing the patient community, academia, and the biopharmaceutical industry. 

Members of the ERC include: Marc Boutin, JD, Chief Executive Officer, National Health Council; John Bridges, PhD, Associate Professor, Johns Hopkins University; Paul Hastings, President and CEO, OncoMed Pharmaceuticals, Inc.; Stacy Holdsworth, PharmD, Senior Advisor, US Regulatory Policy and Strategy, Eli Lilly and Company; Reed Johnson, PhD, Senior Research Scholar, Duke University; Bennett Levitan, MD, PhD, Senior Director, Benefit-Risk Assessment, Janssen Research & Development, LLC, Johnson & Johnson; Kimberly McCleary, Managing Director, FasterCures; Bray Patrick-Lake, Director of Stakeholder Engagement, Clinical Trials Transformation Initiative; and Holly Peay, PhD, Research Analyst, RTI International; Co-PI, DuchenneConnect Registry (a program of PPMD). 

“This project would not have been possible without the generous assistance of these distinguished experts. We greatly appreciate their time, enthusiasm, and passionate commitment to the science of patient input,” said BIO’s Jim Greenwood and PPMD’s Pat Furlong.

The project was led by a team of BIO and PPMD staff, working with WSCollaborative:

  • BIO (E. Cartier Esham, Gautami Inamdar, Lauren Neff, Cara Toman);
  • PPMD (Ryan Fischer, Annie Kennedy, Kaylan Moitoso)
  • WSCollaborative (Wendy Selig, Alexandra Carney)

A panel discussion of the report’s findings featuring members of the ERC, BIO, and PPMD will be held later today at the BIO International Convention, from 3:30-4:30 pm PT in room West 3000 of the Moscone Center.

About PPMD

Parent Project Muscular Dystrophy (PPMD) is the largest most comprehensive nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy – their mission is to end Duchenne. PPMD invests deeply in treatments for this generation of people affected by Duchenne and in research that will benefit future generations. They advocate in Washington, DC, and have secured hundreds of millions of dollars in funding. They demand optimal care, and strengthen, unite and educate the global Duchenne community. Everything PPMD does – and everything they have done since their founding in 1994 – helps people with Duchenne live longer, stronger lives. For more information, visit

Contact: Daniel Seaton (BIO)


Contact: Will Nolan (PPMD)


Discover More
New focus on justice through equity in diverse clinical trials, STEM education and expanding entrepreneurship to undeserved communities will drive nation’s largest life science advocacy organization The Biotechnology Innovation Organization (BIO)…
Today, the Biotechnology Innovation Organization (BIO) submitted its comments in response to the U.S. Department of Agriculture’s (UDSA) Solicitation of Input from Stakeholders on Agricultural Innovations, part of the Department’s Agriculture…
Washington, D.C. (July 29, 2020) – The Food and Agriculture Section of the Biotechnology Innovation Organization (BIO) is pleased to announce the election of its new Board leadership. Sylvia Wulf, CEO of AquaBounty Technologies, Inc., and Brian…